XFOR FY2024 EPS Decreased by Brookline Capital Management

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Management dropped their FY2024 earnings estimates for shares of X4 Pharmaceuticals in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($0.67) per share for the year, down from their prior estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

XFOR has been the subject of a number of other reports. HC Wainwright reduced their price objective on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus lowered their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 9.4 %

Shares of NASDAQ:XFOR opened at $0.64 on Thursday. The firm has a market cap of $108.52 million, a P/E ratio of -7.07 and a beta of 0.14. The business’s 50 day simple moving average is $0.55 and its two-hundred day simple moving average is $0.62. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals in the third quarter worth $30,000. SG Americas Securities LLC purchased a new position in shares of X4 Pharmaceuticals in the third quarter worth $37,000. XTX Topco Ltd bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at $65,000. Rhumbline Advisers boosted its position in X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after purchasing an additional 126,296 shares in the last quarter. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.